SCHEMBL3369103

SCHEMBL3369103

Cc1ccc(-c2nc(CCOc3ccc(C=O)c4sccc34)c(C)s2)cc1

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 20/20 0.43
PPARG P37231 19/20 0.43
PPARD Q03181 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3372208 0.77 PPARG (0.57) PPARAPPARGPPARD
SCHEMBL3370150 0.77 PPARG (0.65) PPARAPPARGPPARD
SCHEMBL3375369 0.77 PPARA (0.42) PPARAPPARGPPARD
SCHEMBL5042459 0.74 PPARG (0.66) PPARAPPARGPPARD
SCHEMBL5563206 0.73 PPARG (0.45) PPARAPPARGPPARD
SCHEMBL5764287 0.72 PPARG (0.55) PPARAPPARGPPARD
SCHEMBL31095000 0.72 PPARG (0.56) PPARAPPARGPPARD
SCHEMBL30193455 0.72 PPARG (0.52) PPARAPPARGPPARD
SCHEMBL3371507 0.70 PPARG (0.73) PPARAPPARGPPARD
SCHEMBL3375444 0.70 PPARG (0.61) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR PPARA 287/4885PPARG 181/4885PPARD 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.